Novo Nordisk (NVO) Stock Rises 6% After Strong Wegovy Sales Data

Novo Nordisk (NVO) raised its full-year 2026 profit guidance following better-than-expected sales of its Wegovy weight-loss pill, which reached 2.26 billion kroner in Q1, above estimates of 1.16 billion kroner. The company's shares increased by 6.3% in morning trading, following prior gains over 8%. Adjusted sales and profits are expected to decline between 4% and 12% on a currency-adjusted basis, improving from prior projections. First-quarter sales were reported at 96.8 billion kroner ($15.2 billion), with operating profit surging 65% to 59.6 billion kroner.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.